IndulgeRx Wins WIPO Patent Sweep for IRX FOODSCORE Platform

IndulgeRx Brands said WIPO published three PCT patent applications for its IRX FOODSCORE platform on July 23, 2026, each backed by an all-A international search report from the U.S. patent authority. The result gives the Utah nutrition-tech company public validation of its IP position as it moves toward investor and partner discussions.

Why it matters: - The WIPO publication gives IndulgeRx a public, government-recorded milestone for its IRX FOODSCORE® platform. - The all-A search reports reduce patent-risk concerns around the company’s core technology. - The result could matter to friends-and-family investors, institutional backers, strategic acquirers, and potential partners evaluating the company’s IP moat. - IndulgeRx says the milestone strengthens its positioning ahead of seed-round and Series A discussions.

What happened: - WIPO published all three of IndulgeRx Brands Inc.’s Patent Cooperation Treaty applications on July 23, 2026. - The applications cover IRX FOODSCORE® as a system, software, and business method. - The U.S. International Searching Authority issued an “all-A” International Search Report for each application. - Each report found every claim novel, inventive, and industrially applicable. - The published WIPO records are available as IRX FS SOFTWARE - WO2026156106 A1, IRX FS METHOD - WO2026156110 A1, and IRX FS SYSTEM - WO2026156104 A1.

The details: - IndulgeRx is a privately held, founder- and friends-and-family-funded nutrition technology company based in Woods Cross, Utah. - Across the three filings, the examiner found zero “X” citations and zero “Y” citations. - All references in the search reports were graded “A,” meaning background material with no direct threat to patentability. - The Written Opinions affirmed novelty, inventive step, and industrial applicability for claims 1–15. - The examiner concluded that combining prior art “would be impermissible hindsight.” - The examiner also wrote that combining existing technologies “would not provide any advantages over the present application, or would require a complexity beyond the level of ordinary skill.” - Patent counsel said one filing needed a minor procedural claim-grouping clarification that did not affect the “A” grades or novelty findings. - IndulgeRx says the patent search looked across health AI names including Medtronic, Oracle, Salesforce, Cornell, and others. - The company says the priority date is January 16, 2025. - IndulgeRx says IRX FOODSCORE® analyzes health history, age, gender, medications, goals, ingredients, additives, preservatives, and preparation methods. - The platform produces two outputs: a Relevant Nutrition Score and a Relevant Risk Score. - IndulgeRx says the system is designed to answer “is this good for me?” with one actionable score worldwide.

Between the lines: - The company is using the patent result as proof that its technology is differentiated, not just another layer on top of existing health-tech tools. - The all-A outcome is notable because patent searches often surface prior art that narrows or weakens claims. - The public publication also creates a clearer reference point for investors and partners weighing the strength of the company’s intellectual property. - The company’s language suggests it wants this result to support both credibility and commercial leverage.

What's next: - IndulgeRx says the patent milestone will support upcoming seed and Series A fundraising conversations. - The company also points to strategic partnership discussions and licensing opportunities across consumer apps, CPG, retail, payers, providers, pharmacists, sports performance, research, and government use cases. - IndulgeRx directs readers to more information at the company’s website, IRX FOODSCORE details, and Fight Back Foods.

The bottom line: - IndulgeRx turned a patent process into a public proof point, and the company is betting that validation will help it attract capital, partners, and customers.